Creatine and guanidinoacetate reference values in a French population

Archive ouverte

Curt, Marie | Cheillan, David | Briand, Gilbert | Salomons, Gajja | Mention-Mulliez, Karine | Dobbelaere, Dries | Cuisset, Jean-Marie | Lion-François, Laurence | Portes, Vincent | Chabli, Allel | Valayannopoulos, Vassili | Benoist, Jean-François | Pinard, Jean-Marc | Simard, Gilles | Douay, Olivier | Deiva, Kumaran | Tardieu, Marc | Afenjar, Alexandra | Héron, Delphine | Rivier, Francois | Chabrol, Brigitte | Prieur, Fabienne | Cartault, François | Pitelet, Gaëlle | Goldenberg, Alice | Bekri, Soumeya | Gerard, Marion | Delorme, Richard | Porchet, Nicole | Vianey-Saban, Christine | Vamecq, Joseph

Edité par CCSD ; Elsevier -

International audience.

Creatine and guanidinoacetate are biomarkers of creatine metabolism. Their assays in body fluids may be used for detecting patients with primary creatine deficiency disorders (PCDD), a class of inherited diseases. Their laboratory values in blood and urine may vary with age, requiring that reference normal values are given within the age range. Despite the long known role of creatine for muscle physiology, muscle signs are not necessarily the major complaint expressed by PCDD patients. These disorders drastically affect brain function inducing, in patients, intellectual disability, autistic behavior and other neurological signs (delays in speech and language, epilepsy, ataxia, dystonia and choreoathetosis), being a common feature the drop in brain creatine content. For this reason, screening of PCDD patients has been repeatedly carried out in populations with neurological signs. This report is aimed at providing reference laboratory values and related age ranges found for a large scale population of patients with neurological signs (more than 6 thousand patients) previously serving as a background population for screening French patients with PCDD. These reference laboratory values and age ranges compare rather favorably with literature values for healthy populations. Some differences are also observed, and female participants are discriminated from male participants as regards to urine but not blood values including creatine on creatinine ratio and guanidinoacetate on creatinine ratio values. Such gender differences were previously observed in healthy populations; they might be explained by literature differential effects of testosterone and estrogen in adolescents and adults, and by estrogen effects in prepubertal age on SLC6A8 function. Finally, though they were acquired on a population with neurological signs, the present data might reasonably serve as reference laboratory values in any future medical study exploring abnormalities of creatine metabolism and transport.

Consulter en ligne

Suggestions

Du même auteur

Screening for primary creatine deficiencies in French patients with unexplained neurological symptoms.

Archive ouverte | Cheillan, David | CCSD

International audience

PFMG2025–integrating genomic medicine into the national healthcare system in France

Archive ouverte | Abadie, Caroline | CCSD

International audience. Integrating genomic medicine into healthcare systems is a health policy challenge that requires continuously transferring scientific advances into clinics and ensuring equal access for patien...

A novel mutation of the ACADM gene (c.145C>G) associated with the common c.985A>G mutation on the other ACADM allele causes mild MCAD deficiency: a case report.

Archive ouverte | Dessein, Anne-Frédérique | CCSD

International audience. A female patient, with normal familial history, developed at the age of 30 months an episode of diarrhoea, vomiting and lethargy which resolved spontaneously. At the age of 3 years, the patie...

Chargement des enrichissements...